Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory for Molecular Medicine, |
RCV000156450 | SCV000206169 | likely benign | not specified | 2014-04-02 | criteria provided, single submitter | clinical testing | Val27680Ile in exon 284 of TTN: This variant is not expected to have clinical si gnificance due to a lack of conservation across species including 10 mammals tha t have an isoleucine (Ile) at this position despite high nearby amino acid conse rvation. |
Labcorp Genetics |
RCV000544571 | SCV000643879 | uncertain significance | Dilated cardiomyopathy 1G; Autosomal recessive limb-girdle muscular dystrophy type 2J | 2017-04-03 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002362831 | SCV002657975 | uncertain significance | Cardiovascular phenotype | 2019-04-16 | criteria provided, single submitter | clinical testing | The p.V21183I variant (also known as c.63547G>A), located in coding exon 162 of the TTN gene, results from a G to A substitution at nucleotide position 63547. The valine at codon 21183 is replaced by isoleucine, an amino acid with highly similar properties. This amino acid position is not well conserved in available vertebrate species, and isoleucine is the reference amino acid in other vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |